ASNDのチャート
ASNDの企業情報
| symbol | ASND |
|---|---|
| 会社名 | Ascendis Pharma A/S （アセンディス・ファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH the Company has developed a pipeline of long-acting prodrug product candidates such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH) TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism a rare endocrine disorder of calcium and phosphate metabolism. アセンディス・ファ―マは、デンマ―クのバイオ医薬品会社。高価値の薬のプロドラッグ・バ―ジョンを開発。小児成長ホルモン欠損症、成人成長ホルモン欠損症、肺動脈高血圧症、糖尿病および眼科の治療のために、独自の「TransCon技術」を用いて、既存の薬物のバ―ジョンを改善した製品候補を生成する。 ascendis pharma a/s is a biotechnology company located in 12 tuborg blvd., hellerup, capital region of denmark, denmark. |
| 本社所在地 | Tuborg Boulevard 5 Hellerup DK-2900 DNK |
| 代表者氏名 | Michael Wolff Jensen マイケル・ウォルフ・イェンセン |
| 代表者役職名 | Chairman of the Board Senior Vice President General Counsel |
| 電話番号 | ― |
| 設立年月日 | 2006年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 137人 |
| url | www.ascendispharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/asnd |
| adr_tso | 39488792 |
| EBITDA | EBITDA（百万ドル） -164.46230 |
| 終値（lastsale） | 66.33 |
| 時価総額（marketcap） | 2619291573.36 |
| 時価総額 | 時価総額（百万ドル） 2731.168 |
| 売上高 | 売上高（百万ドル） 0.87316 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2326.0657 |
| 当期純利益 | 当期純利益（百万ドル） -151.88880 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Ascendis Pharma A/S revenues decreased 94% to EUR46K. Net loss increased 15% to EUR64.2M. Revenues reflect Revenue from the rendering of services decrease of 90% to EUR46K. Higher net loss reflects Research and development costs - Balance increase from EUR20.8M to EUR66.4M (expense) Stock-based Compensation in General increase from EUR1.2M to EUR4.6M (expense). |
ASNDのテクニカル分析
ASNDのニュース
Ascendis Pharma Opens Compassionate Use Program for TransCon PTH (palopegteriparatide) in Germany 2023/06/05 21:30:00 Wallstreet:Online
– Compassionate use enables treating physicians in Germany to request access to investigational TransCon PTH (palopegteriparatide) for eligible adult patients with hypoparathyroidism COPENHAGEN, Denmark, June 05, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has started enrollment for a Compassionate Use Program (CUP) in Germany for TransCon PTH (palopegteriparatide),
Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany 2023/06/05 21:30:00 GlobeNewswire
– Compassionate use enables treating physicians in Germany to request access to investigational TransCon PTH (palopegteriparatide) for eligible adult patients with hypoparathyroidism
Hypoparathyroidism Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Ascendis Pharma, EnteraBio, Bridgebio, Calcil ytix Therapeutics, Ascendis Pharma, Shire, Chugai Pharmaceutical 2023/06/01 11:44:58 OpenPR
DelveInsight''s "Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and
Ascendis Pharma added to Wedbush''s best ideas list 2023/05/08 15:43:09 Seeking Alpha
Wedbush had added Ascendis to its best ideas list, highlighting its TransCon platform and the potential approval of a hypoparathyroidism treatment. Read more here.
Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference 2023/05/03 20:15:00 GlobeNewswire
COPENHAGEN, Denmark, May 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in a virtual fireside chat at the BofA Securities 2023 Health Care Conference on Tuesday, May 9.
Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH 2022/08/31 13:36:40 Seeking Alpha
Danish biotech Ascendis Pharma (ASND) on Wednesday said it had submitted a new drug application to the U.S
Ascendis Pharma Submits TransCon PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism 2022/08/31 12:27:00 Wallstreet:Online
• TransCon PTH could, if approved, become the first hormone replacement therapy to address the underlying cause of hypoparathyroidism, an area of major unmet medical need for the estimated 70,000-90,000 adults living with chronic disease in the United States alone. • European MAA on track for Q4 2022 submission COPENHAGEN, Denmark, Aug. 31, 2022 (GLOBE NEWSWIRE)
Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism 2022/08/31 12:27:00 Ascendis Pharma
• TransCon PTH could , if approved, become the first hormone replacement therapy to address the underlying cause of hypoparathyroidism, an area of major unmet medical need for the estimated 70,000-90,000 adults living with chronic disease in the United States alone.
Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa 2022/08/11 15:18:21 Seeking Alpha
U.S.-listed shares of Ascendis Pharma (ASND) gained 7% to $101.82, after the Danish biotech reported Q2 results that beat estimates, helped by a surge in sales of growth hormone…
Ascendis Pharma PT Lowered to $148 at Morgan Stanley 2022/08/11 08:22:19 Investing.com
https://www.investing.com/news/pro/ascendis-pharma-pt-lowered-to-148-at-morgan-stanley-432SI-2869820
Parametric Portfolio Associates LLC Increases Position in Ascendis Pharma A/S (NASDAQ:ASND) 2021/12/08 11:06:43 Transcript Daily
Parametric Portfolio Associates LLC increased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 38.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,565 shares of the biotechnology companys stock after buying an additional 7,620 shares during the quarter. Parametric []
Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14 2021/12/07 22:41:00 Ascendis Pharma
COPENHAGEN, Denmark , Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on Tuesday, December 14, 2021 . The event will feature updates on Ascendis Pharmas endocrinology rare
-$2.65 Earnings Per Share Expected for Ascendis Pharma A/S (NASDAQ:ASND) This Quarter 2021/12/07 17:48:41 Dakota Financial News
Equities analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will announce earnings of ($2.65) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Ascendis Pharma A/Ss earnings. The highest EPS estimate is ($2.16) and the lowest is ($3.05). Ascendis Pharma A/S posted earnings of ($3.15) per share in the []
Ascendis Pharma A/S (NASDAQ:ASND) Expected to Announce Quarterly Sales of $4.34 Million 2021/12/07 17:48:41 Transcript Daily
Wall Street analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to announce $4.34 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Ascendis Pharma A/Ss earnings, with estimates ranging from $930,000.00 to $9.63 million. Ascendis Pharma A/S posted sales of $640,000.00 in the same quarter last year, []
Ascendis Pharma A/S (ASND) Worth Considering For The Next Few Weeks 2021/12/04 12:00:00 Stocks Register
Ascendis Pharma A/S (NASDAQ:ASND) concluded the trading at $135.61 on Friday, December 03 with a fall of -7.05% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $145.89 and 5Y monthly beta was reading 0.79 with its price kept floating in the Ascendis Pharma A/S (ASND) Worth Considering For The Next Few Weeks Read More »